How Long Does Eliquis Stay in Your System?

The 12-hour half-life, in practical terms

Apixaban's half-life is about 12 hours, and the drug is about 50% bioavailable after an oral dose, with food making no difference [1]. Half-life is the time it takes for the amount of drug in the blood to fall by half, so the decline is predictable in someone whose liver and kidneys work normally:

• 12 hours after a dose: about half remains
• 24 hours: about a quarter
• 36 hours: about one-eighth
• 48 hours: about 6%
• 60 hours: about 3%

The 60-hour mark is where the standard five-half-life rule of thumb puts functional elimination. These are estimates for a typical adult, not a measurement of an individual's blood level, and they assume unchanged liver and kidney function.

Does kidney function change how long Eliquis stays in your system?

About 27% of apixaban clearance is renal. The rest is handled largely by CYP3A4 metabolism, with minor contributions from other enzymes [1].

The label's reduced atrial fibrillation dose is 2.5 mg twice daily instead of 5 mg twice daily. It applies when at least two of the following are present: age 80 or older, body weight 60 kg or less, or serum creatinine 1.5 mg/dL or more [1]. Creatinine is only one of the three criteria.

Medicines that push apixaban levels up or down

Strong inhibitors of both CYP3A4 and P-glycoprotein slow apixaban's removal. In a study of 18 healthy volunteers given apixaban 10 mg, ketoconazole 400 mg daily raised total apixaban exposure (AUC) by 99% and peak concentration by 62% [2]. Diltiazem 360 mg daily, a moderate inhibitor, raised AUC by 40% and peak concentration by 31% [2].

For combined P-gp and strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir), the Eliquis label says to cut the dose by 50% when the patient takes 5 mg or 10 mg twice daily, and to avoid the combination when the patient already takes 2.5 mg twice daily. Clarithromycin is also a combined inhibitor, but the label says no dose adjustment is needed with it [1].

In the other direction, rifampin 600 mg daily cut oral apixaban AUC by 54% in 20 healthy participants, and oral bioavailability fell from 49% to 39% [3]. The label says to avoid combined P-gp and strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin, St. John's wort) because exposure falls and the risk of stroke and other thromboembolic events rises [1].

Real-world data point the same way. In a Belgian nationwide cohort of 193,072 people with atrial fibrillation on DOACs, concomitant P-gp/CYP3A4 inhibitors were associated with more major bleeding (adjusted HR 1.24, 95% CI 1.18-1.30) and inducers with more stroke (adjusted HR 1.31, 95% CI 1.03-1.68). Among apixaban users specifically, the inhibitor hazard ratio for major bleeding was 1.27 (95% CI 1.16-1.39) [4]. These are observational associations, not proof of cause.

Bleeding risk while the drug is still in you

The Eliquis label says it can cause serious, potentially fatal bleeding, and lists aspirin and other antiplatelets, other anticoagulants, heparin, thrombolytics, SSRIs, SNRIs and NSAIDs as adding to that risk [1]. In ARISTOTLE, which randomized 18,201 patients with atrial fibrillation, major bleeding occurred at 2.13% per year on apixaban versus 3.09% per year on warfarin, and stroke or systemic embolism at 1.27% versus 1.60% per year [5].

The label's boxed warning says premature discontinuation of any oral anticoagulant, including Eliquis, increases the risk of thrombotic events. If it is stopped for a reason other than pathological bleeding or completing therapy, the label says to consider coverage with another anticoagulant [1]. A second boxed warning covers spinal or epidural hematomas in patients receiving neuraxial anesthesia or spinal puncture. The risk rises with indwelling epidural catheters, concomitant NSAIDs, platelet inhibitors or other anticoagulants, traumatic or repeated punctures, and spinal deformity or surgery [1].

Reversal and monitoring

The label says the specific reversal agent andexanet alfa is available for adults. It also says protamine sulfate and vitamin K are not expected to affect apixaban's activity, and that PT, INR, aPTT and anti-factor Xa tests are not useful for monitoring when prothrombin complex concentrates are used [1]. Unlike warfarin, there are no vitamin K diet rules and no INR targets.